Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

The Journal of Antibiotics
  • View all journals
  • Search
  • Log in
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. the journal of antibiotics
  3. original article
  4. article
A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis
Download PDF
Download PDF
  • Original Article
  • Published: 01 July 2008

A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis

  • Masayuki Arakawa1,
  • Tetsuya Someno1,
  • Manabu Kawada1 &
  • …
  • Daishiro Ikeda1 

The Journal of Antibiotics volume 61, pages 442–448 (2008)Cite this article

  • 1683 Accesses

  • 53 Citations

  • Metrics details

Abstract

Angiogenesis is a critical step for the tumor therapy. Many angiogenic factors are involved in the tumor angiogenesis. In the course of our screening for inhibitors of angiogenin secretion, one of angiogenic factors, we have isolated a new terrein glucoside (1) and terrein (2) from the fermentation broth of fungal strain Aspergillus sp. PF1381. The structure and absolute stereochemistry of 1 was determined to be (4S,5R)-5-[(α-D-glucopyranosyl)oxy]-4-hydroxy-3-(E-1-propenyl)-2-cyclopenten-1-one on the basis of spectral and enzymatic analyses. Compounds 1 and 2 equally inhibited angiogenin secretion from androgen-dependent prostate cancer cells, LNCaP-CR, with IC50 values of 13 μM. However, both compounds did not affect VEGF secretion, another angiogenic factor. Furthermore, both compounds inhibited tube formation of human umbilical vein endothelial cells (HUVEC). These results suggested that 1 and 2 act as angiogenesis inhibitors through the inhibition of angiogenin secretion.

Similar content being viewed by others

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

Article Open access 11 May 2023

A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy

Article Open access 06 October 2022

An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis

Article Open access 29 April 2023

Article PDF

References

  1. Berger G, Benjamin LE . Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 3: 401–410 ( 2003)

    Article  Google Scholar 

  2. Folkman J . Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15–18 ( 2002)

    Article  CAS  Google Scholar 

  3. Folkman J . Angiogenesis and angiogenesis inhibition: an overview. EXS 79: 1–8 ( 1997)

    CAS  PubMed  Google Scholar 

  4. Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nature Reviews Cancer 2: 795–803 ( 2002)

    Article  CAS  Google Scholar 

  5. Chiarugi V, Magnelli L, Gallo O . Cox-2, iNOS and p53 as play-markers of tumor angiogenesis. Int J Mol Med 2: 715–719 ( 1998)

    CAS  PubMed  Google Scholar 

  6. Singh RP, Agarwal R . Prostate cancer prevention by silibinin. Current Cancer Drug Targets 4: 1–11 ( 2005)

    Article  Google Scholar 

  7. Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK, Meydani M . Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 118: 1635–1644 ( 2006)

    Article  CAS  Google Scholar 

  8. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL . Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochem 24: 5480–5486 ( 1985)

    Article  CAS  Google Scholar 

  9. Shapiro R, Riordan JF, Vallee BL . Characteristic ribonucleolytic activity of human angiogenin. Biochem 25: 3527–3532 ( 1986)

    Article  CAS  Google Scholar 

  10. Yoshioka N, Wang Li, Kishimoto K, Tsuji T, Hu G . A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 103: 14519–14524 ( 2006)

    Article  CAS  Google Scholar 

  11. Horner JJ, Greenman J, Stafford ND . Angiogenic cytokines in serum and plasma of patients with head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 25: 570–576 ( 2000)

    Google Scholar 

  12. Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M . Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114: 290–295 ( 2001)

    Article  CAS  Google Scholar 

  13. Zhao H, Grossman HB, Delclos GL, Hwang LY, Troisi CL, Chamberlain RM, Chenoweth MA, Zhang H, Spitz MR, Wu X . Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation to recurrence. Cancer 104: 30–35 ( 2005)

    Article  CAS  Google Scholar 

  14. Kawada M, Inoue H, Usami I, Takamoto K, Masuda T, Yamazaki Y, Ikeda D . Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance. Cancer Lett 242: 46–52 ( 2006)

    Article  CAS  Google Scholar 

  15. Kawada M, Inoue H, Arakawa M, Takamoto K, Masuda T, Ikeda D . Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress angiogenin. Cancer Sci 98: 350–356 ( 2007)

    Article  CAS  Google Scholar 

  16. Miwa I, Okuda J, Maeda K, Okuda G . Mutarotase effect on colorimetric determination of blood glucose with -D-glucose oxidase. Clin Chim Acta 37: 538–540 ( 1972)

    Article  CAS  Google Scholar 

  17. Kolb HC, Hoffman MR . A total synthesis of racemic and optically active terrein (trans-4,5-dihydroxy-3-[(E)-1- propenyl]-2-cyclopenten-1-one). Tetrahedron: Symmetry 1: 237–250 ( 1990)

    Article  CAS  Google Scholar 

  18. Raistrick H, Smith G . Biochemistry of microorganisms. XLII. The metabolic products of Aspergillus terreus Thom: a new mold metabolic product-terrein. Biochem J 29: 606–611 ( 1935)

    Article  CAS  Google Scholar 

  19. Kawakubo J, Nishira H, Aoki K, Shinke R . Production of phenolic compounds by Aspergillus S-4 in sake-cake medium and identification of terrein. Biosci Biotec Biochem 57: 1208–1209 ( 1993)

    Article  CAS  Google Scholar 

  20. Park SH, Kim DS, Kim WG, Ryoo IJ, Lee DH, Huh CH, Youn SW, Yoo ID, Park KC . Terrein: a new melanogenesis inhibitor and its mechanism. Cell Mol Life Sci 61: 2878–2885 ( 2004)

    Article  CAS  Google Scholar 

  21. Kim DS, Cho HJ, Lee HK, Lee WH, Park ES, Youn SW, Park KC . Terrein, a fungal metabolite, inhibits the epidermal proliferation of skin equivalents. J Dermatol Sci 46: 65–68 ( 2007)

    Article  CAS  Google Scholar 

  22. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF . Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24: 445–456 ( 2005)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Drug Development Unit, Numazu Bio-Medical Research Institute, Microbial Chemistry Research Center, 18-24 Miyamoto, Numazu-shi, Shizuoka, 410-0301, Japan

    Masayuki Arakawa, Tetsuya Someno, Manabu Kawada & Daishiro Ikeda

Authors
  1. Masayuki Arakawa
    View author publications

    Search author on:PubMed Google Scholar

  2. Tetsuya Someno
    View author publications

    Search author on:PubMed Google Scholar

  3. Manabu Kawada
    View author publications

    Search author on:PubMed Google Scholar

  4. Daishiro Ikeda
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Manabu Kawada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arakawa, M., Someno, T., Kawada, M. et al. A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis. J Antibiot 61, 442–448 (2008). https://doi.org/10.1038/ja.2008.60

Download citation

  • Received: 10 April 2008

  • Accepted: 01 July 2008

  • Issue date: 01 July 2008

  • DOI: https://doi.org/10.1038/ja.2008.60

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • angiogenin
  • terrein glucoside
  • angiogenesis
  • angiogenic factors
  • prostate cancer

This article is cited by

  • Unearthing the fungal endophyte Aspergillus terreus for chemodiversity and medicinal prospects: a comprehensive review

    • Khadiga Amr
    • Nehal Ibrahim
    • Abdel Nasser B. Singab

    Fungal Biology and Biotechnology (2023)

  • Genetic and Histopathological Alterations in Caco-2 and HuH-7 Cells Treated with Secondary Metabolites of Marine fungi

    • Aly Fahmy Mohamed
    • Tamer M. M. Abuamara
    • Mohammed Abu-Elghait

    Journal of Gastrointestinal Cancer (2022)

  • Induced terreins production from marine red algal-derived endophytic fungus Aspergillus terreus EN-539 co-cultured with symbiotic fungus Paecilomyces lilacinus EN-531

    • Hong-Lei Li
    • Xiao-Ming Li
    • Bin-Gui Wang

    The Journal of Antibiotics (2020)

  • The catalytic activity and secretion of zebrafish RNases are essential for their in vivo function in motor neurons and vasculature

    • Ross Ferguson
    • Daniel E. Holloway
    • Vasanta Subramanian

    Scientific Reports (2019)

  • Improving the yield of (+)-terrein from the salt-tolerant Aspergillus terreus PT06-2

    • Chengying Zhao
    • Lei Guo
    • Weiming Zhu

    World Journal of Microbiology and Biotechnology (2016)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open Access Fees and Funding
  • About the Editors
  • Contact
  • About the Partners
  • For Advertisers
  • Subscribe
  • JA Ōmura Award winners
  • Featured Articles

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

The Journal of Antibiotics (J Antibiot)

ISSN 1881-1469 (online)

ISSN 0021-8820 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited